메뉴 건너뛰기




Volumn 14, Issue 6, 2015, Pages 1454-1465

MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast Cancer

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FUROSEMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PROTEASOME; PROTEIN MAP17; TUMOR MARKER; UNCLASSIFIED DRUG; PDZK1IP1 PROTEIN, HUMAN; PROTEASOME INHIBITOR;

EID: 84942155861     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1053     Document Type: Article
Times cited : (26)

References (51)
  • 2
    • 84860436602 scopus 로고    scopus 로고
    • Advances in the understanding of mechanisms and therapeutic use of bortezomib
    • Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;12:471-80.
    • (2011) Discov Med , vol.12 , pp. 471-480
    • Mujtaba, T.1    Dou, Q.P.2
  • 3
    • 27944431658 scopus 로고    scopus 로고
    • Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
    • Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005;31:591-602.
    • (2005) Cancer Treat Rev , vol.31 , pp. 591-602
    • Jackson, G.1    Einsele, H.2    Moreau, P.3    Miguel, J.S.4
  • 4
    • 33644845743 scopus 로고    scopus 로고
    • Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
    • Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-6.
    • (2006) Structure , vol.14 , pp. 451-456
    • Groll, M.1    Berkers, C.R.2    Ploegh, H.L.3    Ovaa, H.4
  • 5
    • 0033817518 scopus 로고    scopus 로고
    • Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341
    • Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.
    • (2000) Clin Cancer Res , vol.6 , pp. 3719-3728
    • Frankel, A.1    Man, S.2    Elliott, P.3    Adams, J.4    Kerbel, R.S.5
  • 6
    • 0036181371 scopus 로고    scopus 로고
    • Development of the proteasome inhibitor PS-341
    • Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
    • (2002) Oncologist , vol.7 , pp. 9-16
    • Adams, J.1
  • 8
    • 0034902354 scopus 로고    scopus 로고
    • Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
    • Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
    • (2001) Clin Cancer Res , vol.7 , pp. 1419-1428
    • Sunwoo, J.B.1    Chen, Z.2    Dong, G.3    Yeh, N.4    Crowl Bancroft, C.5    Sausville, E.6
  • 9
    • 21344469223 scopus 로고    scopus 로고
    • Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiplemyeloma
    • Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiplemyeloma. Br J Haematol 2005;129:776-83.
    • (2005) Br J Haematol , vol.129 , pp. 776-783
    • Jagannath, S.1    Durie, B.G.2    Wolf, J.3    Camacho, E.4    Irwin, D.5    Lutzky, J.6
  • 10
    • 18144431710 scopus 로고    scopus 로고
    • Mitochondrialmediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines
    • Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrialmediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-36.
    • (2005) Cancer Res , vol.65 , pp. 3828-3836
    • Landowski, T.H.1    Megli, C.J.2    Nullmeyer, K.D.3    Lynch, R.M.4    Dorr, R.T.5
  • 11
    • 53349101501 scopus 로고    scopus 로고
    • Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells
    • Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008;7:2298-307.
    • (2008) Mol Cancer Ther , vol.7 , pp. 2298-2307
    • Gu, H.1    Chen, X.2    Gao, G.3    Dong, H.4
  • 13
    • 2342667387 scopus 로고    scopus 로고
    • The development of proteasome inhibitors as anticancer drugs
    • Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
    • (2004) Cancer Cell , vol.5 , pp. 417-421
    • Adams, J.1
  • 14
    • 0027980321 scopus 로고
    • The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
    • Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
    • (1994) Cell , vol.78 , pp. 773-785
    • Palombella, V.J.1    Rando, O.J.2    Goldberg, A.L.3    Maniatis, T.4
  • 15
    • 0346505340 scopus 로고    scopus 로고
    • The IKK NF-kappa B system: A treasure trove for drug development
    • Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
    • (2004) Nat Rev Drug Discov , vol.3 , pp. 17-26
    • Karin, M.1    Yamamoto, Y.2    Wang, Q.M.3
  • 16
    • 0037342894 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    • Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
    • (2003) Clin Cancer Res , vol.9 , pp. 1136-1144
    • Ma, M.H.1    Yang, H.H.2    Parker, K.3    Manyak, S.4    Friedman, J.M.5    Altamirano, C.6
  • 17
    • 0033121314 scopus 로고    scopus 로고
    • Role of NFkappaB in the rescue of multiple myeloma cells from glucocorticoidinduced apoptosis by bcl-2
    • Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NFkappaB in the rescue of multiple myeloma cells from glucocorticoidinduced apoptosis by bcl-2. Blood 1999;93:3044-52.
    • (1999) Blood , vol.93 , pp. 3044-3052
    • Feinman, R.1    Koury, J.2    Thames, M.3    Barlogie, B.4    Epstein, J.5    Siegel, D.S.6
  • 18
    • 84857668451 scopus 로고    scopus 로고
    • Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells
    • Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS One 2012;7:e32584.
    • (2012) PLoS One , vol.7 , pp. e32584
    • Jia, L.1    Gopinathan, G.2    Sukumar, J.T.3    Gribben, J.G.4
  • 19
    • 22244454745 scopus 로고    scopus 로고
    • Differential regulation of noxa in normalmelanocytes andmelanoma cells by proteasome inhibition: Therapeutic implications
    • Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, et al. Differential regulation of noxa in normalmelanocytes andmelanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
    • (2005) Cancer Res , vol.65 , pp. 6294-6304
    • Fernandez, Y.1    Verhaegen, M.2    Miller, T.P.3    Rush, J.L.4    Steiner, P.5    Opipari, A.W.6
  • 21
    • 84857368471 scopus 로고    scopus 로고
    • Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
    • Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, et al. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med 2012;90:45-54.
    • (2012) J Mol Med , vol.90 , pp. 45-54
    • Befani, C.D.1    Vlachostergios, P.J.2    Hatzidaki, E.3    Patrikidou, A.4    Bonanou, S.5    Simos, G.6
  • 22
    • 77951598447 scopus 로고    scopus 로고
    • The chemotherapeutic agent bortezomib induces the formation of stress granules
    • Fournier MJ, Gareau C, Mazroui R. The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int 2010;10:12.
    • (2010) Cancer Cell Int , vol.10 , pp. 12
    • Fournier, M.J.1    Gareau, C.2    Mazroui, R.3
  • 23
    • 17844399285 scopus 로고    scopus 로고
    • The enigmatic role of cyclin D1 in multiple myeloma
    • Lesage D, Troussard X, Sola B. The enigmatic role of cyclin D1 in multiple myeloma. Int J Cancer 2005;115:171-6.
    • (2005) Int J Cancer , vol.115 , pp. 171-176
    • Lesage, D.1    Troussard, X.2    Sola, B.3
  • 24
    • 33644875054 scopus 로고    scopus 로고
    • Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    • O'Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005;6:191-9.
    • (2005) Clin Lymphoma Myeloma , vol.6 , pp. 191-199
    • O'Connor, O.A.1
  • 26
    • 0028871496 scopus 로고
    • Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique
    • Kocher O, Cheresh P, Brown LF, Lee SW. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res 1995;1:1209-15.
    • (1995) Clin Cancer Res , vol.1 , pp. 1209-1215
    • Kocher, O.1    Cheresh, P.2    Brown, L.F.3    Lee, S.W.4
  • 27
    • 0030017442 scopus 로고    scopus 로고
    • Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth
    • Kocher O, Cheresh P, Lee SW. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol 1996;149:493-500.
    • (1996) Am J Pathol , vol.149 , pp. 493-500
    • Kocher, O.1    Cheresh, P.2    Lee, S.W.3
  • 28
    • 36949008406 scopus 로고    scopus 로고
    • MAP17 inhibits Mycinduced apoptosis through PI3K/AKT pathway activation
    • Guijarro MV, Link W, Rosado A, Leal JF, Carnero A. MAP17 inhibits Mycinduced apoptosis through PI3K/AKT pathway activation. Carcinogenesis 2007;28:2443-50.
    • (2007) Carcinogenesis , vol.28 , pp. 2443-2450
    • Guijarro, M.V.1    Link, W.2    Rosado, A.3    Leal, J.F.4    Carnero, A.5
  • 29
    • 0033832036 scopus 로고    scopus 로고
    • The membrane-associated protein pKe 92/MAP17 in human keratinocytes
    • Jaeger C, Schaefer BM, Wallich R, Kramer MD. The membrane-associated protein pKe 92/MAP17 in human keratinocytes. J Invest Dermatol 2000;115:375-80.
    • (2000) J Invest Dermatol , vol.115 , pp. 375-380
    • Jaeger, C.1    Schaefer, B.M.2    Wallich, R.3    Kramer, M.D.4
  • 30
    • 33846210072 scopus 로고    scopus 로고
    • Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi
    • Lanaspa MA, Giral H, Breusegem SY, Halaihel N, Baile G, Catalan J, et al. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am J Physiol Renal Physiol 2007;292:F230-42.
    • (2007) Am J Physiol Renal Physiol , vol.292 , pp. F230-F242
    • Lanaspa, M.A.1    Giral, H.2    Breusegem, S.Y.3    Halaihel, N.4    Baile, G.5    Catalan, J.6
  • 32
    • 84859497390 scopus 로고    scopus 로고
    • MAP17 and the double-edged sword of ROS
    • Carnero A. MAP17 and the double-edged sword of ROS. Biochim Biophys Acta 2012;1826:44-52.
    • (2012) Biochim Biophys Acta , vol.1826 , pp. 44-52
    • Carnero, A.1
  • 38
    • 33846438202 scopus 로고    scopus 로고
    • Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
    • Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339-48.
    • (2007) J Cell Biochem , vol.100 , pp. 339-348
    • Moneo, V.1    Serelde, B.G.2    Fominaya, J.3    Leal, J.F.4    Blanco-Aparicio, C.5    Romero, L.6
  • 39
    • 67849130563 scopus 로고    scopus 로고
    • ToppGene suite for gene list enrichment analysis and candidate gene prioritization
    • Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009;37:W305-11.
    • (2009) Nucleic Acids Res , vol.37 , pp. W305-W311
    • Chen, J.1    Bardes, E.E.2    Aronow, B.J.3    Jegga, A.G.4
  • 40
    • 34147129816 scopus 로고    scopus 로고
    • Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    • Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
    • (2007) Blood , vol.109 , pp. 3177-3188
    • Mulligan, G.1    Mitsiades, C.2    Bryant, B.3    Zhan, F.4    Chng, W.J.5    Roels, S.6
  • 41
    • 84894486878 scopus 로고    scopus 로고
    • IKKbeta inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
    • Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, et al. IKKbeta inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol 2014;44:1171-6.
    • (2014) Int J Oncol , vol.44 , pp. 1171-1176
    • Hideshima, H.1    Yoshida, Y.2    Ikeda, H.3    Hide, M.4    Iwasaki, A.5    Anderson, K.C.6
  • 42
    • 70349243697 scopus 로고    scopus 로고
    • Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    • Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-52.
    • (2009) Blood , vol.114 , pp. 1046-1052
    • Hideshima, T.1    Ikeda, H.2    Chauhan, D.3    Okawa, Y.4    Raje, N.5    Podar, K.6
  • 43
    • 66249085237 scopus 로고    scopus 로고
    • The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib
    • Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res 2009;69:4415-23.
    • (2009) Cancer Res , vol.69 , pp. 4415-4423
    • Milani, M.1    Rzymski, T.2    Mellor, H.R.3    Pike, L.4    Bottini, A.5    Generali, D.6
  • 44
    • 78650041246 scopus 로고    scopus 로고
    • Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
    • David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, et al. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 2010;116:5285-8.
    • (2010) Blood , vol.116 , pp. 5285-5288
    • David, E.1    Kaufman, J.L.2    Flowers, C.R.3    Schafer-Hales, K.4    Torre, C.5    Chen, J.6
  • 46
    • 84893825919 scopus 로고    scopus 로고
    • The four faces of autophagy: Implications for cancer therapy
    • Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014;74:647-51.
    • (2014) Cancer Res , vol.74 , pp. 647-651
    • Gewirtz, D.A.1
  • 47
    • 84878658221 scopus 로고    scopus 로고
    • Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo
    • Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 2013;71:1567-76.
    • (2013) Cancer Chemother Pharmacol , vol.71 , pp. 1567-1576
    • Escalante, A.M.1    McGrath, R.T.2    Karolak, M.R.3    Dorr, R.T.4    Lynch, R.M.5    Landowski, T.H.6
  • 48
    • 7644242953 scopus 로고    scopus 로고
    • Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
    • Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
    • (2004) Mol Cell Biol , vol.24 , pp. 9695-9704
    • Fribley, A.1    Zeng, Q.2    Wang, C.Y.3
  • 49
    • 33744539521 scopus 로고    scopus 로고
    • Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
    • Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
    • (2006) Blood , vol.107 , pp. 4907-4916
    • Obeng, E.A.1    Carlson, L.M.2    Gutman, D.M.3    Harrington, W.J.4    Lee, K.P.5    Boise, L.H.6
  • 50
    • 79960982758 scopus 로고    scopus 로고
    • Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
    • Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 2011;17:5101-12.
    • (2011) Clin Cancer Res , vol.17 , pp. 5101-5112
    • Weniger, M.A.1    Rizzatti, E.G.2    Perez-Galan, P.3    Liu, D.4    Wang, Q.5    Munson, P.J.6
  • 51
    • 77955712506 scopus 로고    scopus 로고
    • Bortezomibresistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
    • Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomibresistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010;24:1506-12.
    • (2010) Leukemia , vol.24 , pp. 1506-1512
    • Ri, M.1    Iida, S.2    Nakashima, T.3    Miyazaki, H.4    Mori, F.5    Ito, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.